Draft MHPD Guidance “Reporting Adverse Reactions to Marketed Health Products”- What’s New?

Life Sciences, Pharma, Pharmacovigilance,
  • Monday, April 19, 2021

Since the MHPD guidance Reporting Adverse Reactions to Marketed Health Products was last published in 2018, Health Canada has identified several elements of the guidance that require updates to further clarify adverse reaction reporting requirements. Consequently, a draft guidance was issued in January 2021 for consultation. This consultation is looking for feedback on the proposed updates to ensure they are clear and relevant and support understanding of the regulatory reporting requirements for industry. The consultation period closes on 25 April 2021. Join our experts to learn about the changes and implications of the updated MHPD draft guidance.  Come prepared to ask questions to the speakers and to Certus PV founding  partners Agnes Jankowicz, M.Sc., Vice President of Pharmacovigilance and Rita Cassola, B.Pharm. (Hons.), Vice President of Pharmacovigilance.

Speakers

Anna Bussel, PV & MI Manager, Certus PV

Anna Bussel, PV & MI Manager, Certus PV

Anna Bussel is a Pharmacovigilance and Medical Information Manager at Certus PV, a Veristat Company. She holds a Master’s Degree in Pharmacy and has over 10 years of experience in Pharmacovigilance, Regulatory Affairs and Product Quality from Europe, Canada, and the US. Anna’s pharmacovigilance expertise includes medical assessments of Individual Case Safety Reports, aggregate report preparation, screening and processing of the Canada Vigilance Adverse Reaction Online Database, literature screening, compliance management, and GVP auditing.

Message Presenter
Elisabete Rego, Certus PV

Elisabete Rego, PV & MI Manager, Certus PV

Elisabete Rego is a Pharmacovigilance and Medical Information Manager at Certus PV, a Veristat Company.  She holds a Master’s degree in Biomedical Sciences. Elisabete is an accomplished bilingual Pharmacovigilance and Medical Information professional with over 6 years of experience in the industry combined with extensive scientific knowledge in several therapeutic areas. Elisabete leads complex Pharmacovigilance and Medical Information projects while ensuring regulatory and contractual compliance.

Message Presenter

Who Should Attend?

  • Pharmacovigilance
  • Product Safety
  • Regulatory Affairs
  • Risk Management

What You Will Learn

  • Discuss proposed changes to the reporting requirements
  • Analyze impact of the proposed changes on the industry
  • Compile feedback resulting form the webinar discussion for the purpose of submission of comment to Health Canada

Xtalks Partner

Certus PV, a Veristat Company

Certus PV, a Veristat Company provides pre-approval and post-market pharmacovigilance (PV) expertise for pharmaceutical drugs (brand and generic), biologics, radiopharmaceutical drugs, natural health products, and medical devices. Our experts help you manage the safety risks of your products before and after they enter the market to ensure compliance with regulatory requirements.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account